Income Taxes (Tables)

12 Months Ended

Dec. 31, 2017

Income Taxes Tables [Abstract]

Schedule of Components of Deferred Tax Assets and Liabilities

Significant components of the Company’s deferred tax assets and liabilities are as follows:

	December 31,
	2017			2016
Deferred tax assets:
Net operating loss carry forwards	$	1,843,000		$	537,000
Capitalized research and development costs		12,177,000			2,532,000
Accrued liabilities		25,000			15,000
Tax credit carryforwards		3,286,000			1,683,000
Stock-based compensation		116,000			38,000
Total deferred tax assets		17,447,000			4,805,000
Valuation allowance		(17,444,000	)		(4,805,000	)
Net deferred tax assets		3,000			—
Deferred tax liabilities		(3,000	)		—
	$	—		$	—

Schedule of Reconciliation of Effective Income Tax Rate

A reconciliation of the U.S. federal statutory tax rate to the effective tax rate is as follows:

	December 31,
	2017			2016
Federal statutory rate		34.0	%		34.0	%
R&D and Orphan drug credits		7.6	%		15.8	%
State income tax, net of federal tax benefit		-0.2	%		-17.7	%
Valuation allowance		18.2	%		137.1	%
Reduction in tax attributed related to deconsolidation of subsidiary		0.0	%		-169.0	%
Tax reform impact		-57.8	%		0.0	%
Other, net		-1.8	%		-0.2	%
Effective tax rate		0.0	%		0.0	%